Sangamo Therapeutics, Inc. Common Stock (SGMO) Stock Price

SGMOStock

$0.16−72.71%52W

Market Cap$66.29M

P/E—

PEG Ratio—

Div yield—

Beta1.56

SGMO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-67.12%

Price vs S&P 500 (4W)135.04%

VGM Score41.17

Book Value / Share (Quarterly)$0.02

P/TBV (Annual)9.35x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-29.17%

Cash Flow / Share (Quarterly)$-0.22

Price vs S&P 500 (YTD)-73.86%

Net Profit Margin (TTM)-356.89%

EPS (TTM)$-0.38

10-Day Avg Trading Volume4.98M

EPS Excl Extra (TTM)$-0.38

Revenue Growth (5Y)-19.66%

EPS (Annual)$-0.44

ROI (Annual)-430.13%

Net Profit Margin (5Y Avg)-192.08%

Cash / Share (Quarterly)$0.07

Revenue Growth QoQ (YoY)-77.60%

ROA (Last FY)-205.76%

Revenue Growth TTM (YoY)-45.80%

EBITD / Share (TTM)$-0.37

ROE (5Y Avg)-175.64%

Operating Margin (TTM)-357.55%

Cash Flow / Share (Annual)$-0.28

P/B Ratio4.86x

P/B Ratio (Quarterly)32.54x

Net Income / Employee (Annual)$-865,700

EV / Revenue (TTM)0.08x

Net Interest Coverage (TTM)-222.00x

ROA (TTM)-161.26%

EPS Incl Extra (Annual)$-0.44

Current Ratio (Annual)0.84x

Quick Ratio (Quarterly)0.64x

3-Month Avg Trading Volume7.90M

52-Week Price Return-72.71%

Revenue / Employee (TTM)$243,400

Tangible BV / Share (Quarterly)$0.11

P/S Ratio (Annual)0.77x

Asset Turnover (Annual)0.66x

52-Week High$0.77

Operating Margin (5Y Avg)-197.67%

EPS Excl Extra (Annual)$-0.44

CapEx CAGR (5Y)-63.00%

Tangible BV CAGR (5Y)-43.03%

26-Week Price Return-55.87%

Quick Ratio (Annual)0.74x

13-Week Price Return2.56%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.70x

Enterprise Value$2.74M

Revenue / Share Growth (5Y)-30.64%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)-50.84%

Revenue / Employee (Annual)$278,500

Pretax Margin (Annual)-312.25%

Cash / Share (Annual)$0.06

3-Month Return Std Dev217.22%

Net Income / Employee (TTM)$-868,500

ROE (Last FY)-430.13%

EPS Basic Excl Extra (Annual)$-0.44

P/FCF (TTM)2.60x

Receivables Turnover (TTM)55.78x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.38

Receivables Turnover (Annual)88.19x

ROI (TTM)-813.95%

P/S Ratio (TTM)0.88x

Pretax Margin (5Y Avg)-192.86%

Revenue / Share (Annual)$0.14

Tangible BV / Share (Annual)$0.11

Price vs S&P 500 (52W)-91.02%

Year-to-Date Return-61.90%

5-Day Price Return0.31%

EPS Normalized (Annual)$-0.44

ROA (5Y Avg)-103.40%

Net Profit Margin (Annual)-310.81%

Month-to-Date Return118.58%

Cash Flow / Share (TTM)$-1.36

EBITD / Share (Annual)$-0.42

Operating Margin (Annual)-306.53%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-175.64%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.38

P/TBV (Quarterly)9.35x

P/B Ratio (Annual)9.35x

Pretax Margin (TTM)-358.88%

Book Value / Share (Annual)$0.11

Price vs S&P 500 (13W)-0.23%

Beta1.56x

P/FCF (Annual)0.20x

Revenue / Share (TTM)$0.09

ROE (TTM)-813.95%

52-Week Low$0.03

vGradeB

gGradeF

mGradeD

vgmGradeC

SGMO Earnings Surprise History

Q2 25-0.08est. -0.13

Q3 25-0.11est. -0.10

Q4 25-0.07est. -0.05

Q1 26-0.08est. -0.07

SGMO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
SGMOSangamo Therapeutics, Inc. Common Stock	B	F	D	$0.16
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Sangamo Therapeutics, Inc. Common Stock

Sangamo Therapeutics is a genomic medicine company developing gene-based therapies for serious genetic and neurological diseases. Its pipeline includes programs in neurology (chronic neuropathic pain, prion disease, ALS, FTD, Huntington's disease), hematology (hemophilia A), and other indications including Fabry disease and multiple sclerosis, with several programs advanced through partnerships.